It would mark the third consecutive year of proposed reductions, which the Justice Department says would help reduce the amount of drugs potentially diverted for trafficking and used to facilitate addiction.
The U.S. Department of Justice is calling for a reduction for controlled substances that may be manufactured in the U.S. next year, Axios reports. Under President Trump’s ‘Safe Prescribing Plan’ that seeks to cut nationwide opioid prescription fills by one-third within three years, the proposal would lower manufacturing quotas for the six most frequently misused opioids for 2019 by an average ten percent as compared to the 2018 amount.
It would mark the third consecutive year of proposed reductions, which DOJ says would help reduce the amount of drugs potentially diverted for trafficking and used to facilitate addiction. The Drug Enforcement Administration says that revised limits “will encourage vigilance on the part of opioid manufacturers, help DEA respond to the changing drug threat environment, and protect the American people from potential addictive drugs while ensuring that the country has enough opioids for legitimate medical, scientific, research, and industrial needs.” The biggest problem remains synthetic opioids like fentanyl. About 30,000 people fatally overdosed on synthetic opioids last year, about the same number as heroin and prescription opioids combined. (Some people are counted multiple times because multiple drugs were in their systems when they died.) Fentanyl is easy to make and ship, it is incredibly potent, and it appears in different places, at different strengths.